Bortezomib

This page provides brief information on bortezomib, covering its prescribed use, recommended dosage and administration, mechanism of action, associated brands and their strengths, precautionary warnings, and typical side effects.

Context and Approval Date

Bortezomib was first approved by the U.S. FDA in May 2003 for the treatment of multiple myeloma. Its approval later expanded to include mantle cell lymphoma and other hematologic malignancies.

Mechanism of Action of Bortezomib

Bortezomib is a proteasome inhibitor
  • Cancer cells rely on proteasomes to degrade misfolded or damaged proteins.
  • By blocking the 26S proteasome, bortezomib disrupts protein homeostasis, leading to accumulation of toxic proteins.
  • This triggers apoptosis (programmed cell death), particularly in rapidly dividing malignant plasma cells.

    • All Substitutes

    View All
    Product Packaging Size Manufacturer Price
    Bortrac 2 2mg Injection 1 Vial(s) Glenmark Pharmaceuticals INR 1800
    Borviz 2mg Injection 1 Vial(s) Intas Pharmaceuticals INR 1030
    Tezomib 2mg Injection 1 Vial(s) BDR Pharmaceuticals INR 990

    Uses of Bortezomib

    Bortezomib is a targeted anticancer medicine used in:
  • Multiple myeloma (newly diagnosed and relapsed/refractory cases).
  • Mantle cell lymphoma (in patients who have received at least one prior therapy). It is often used in combination with other agents such as dexamethasone, lenalidomide, or cyclophosphamide.

    • Administration Guidelines and Dosage Options

    Administration Guide
  • Administered by intravenous (IV) injection or subcutaneous (SC) injection.
  • Dosing schedules vary (once or twice weekly) depending on treatment protocol.
  • Patients should be monitored closely for blood counts, neuropathy, and organ function.
  • Do not self‑administer; treatment must be given under medical supervision.

    • Available Dosage Options

  • Vials containing 3.5 mg powder for reconstitution.
  • Typical adult dose: 1.3 mg/m² body surface area, given twice weekly for 2 weeks, followed by a 10‑day rest period (21‑day cycle).
  • Dose adjustments may be required for:
  • Side effects (e.g., neuropathy, thrombocytopenia).
  • Liver impairment.
  • Combination therapy protocols.

    • Information about Bortezomib

    Bortezomib Uses

    Bortezomib is a medicine used to treat certain blood cancers, including multiple myeloma and mantle‑cell lymphoma. It works by blocking cancer cells from growing and multiplying, which helps slow down the disease and improve patient outcomes.

    How Bortezomib works

    Bortezomib Injection is an anti‑cancer medicine. It works by blocking or slowing the breakdown of proteins inside cells. When this happens, proteins build up in the cancer cells, which causes the cancer cells to stop growing and eventually die.

    Common side effects of Bortezomib

    Common side effects include severe digestive problems (nausea, diarrhea, constipation), peripheral neuropathy (numbness, tingling, or pain in hands and feet), fatigue, low platelets (thrombocytopenia), and low white blood cells (neutropenia).
  • Bortezomib is given as an injection into a vein or just under the skin, always by a doctor or nurse.
  • Take Bortezomib exactly as prescribed don’t skip any doses and make sure to finish the full course recommended by your doctor.
  • Use reliable birth control to prevent pregnancy while receiving Bortezomib treatment.
  • During treatment with Bortezomib, your doctor may ask for regular blood tests to check your blood cells, platelet count, and how well your liver and kidneys are working.
  • Tell your doctor right away if you notice coughing, trouble breathing, or swelling in your feet.

    • Warnings, Precautions, and Side Effects

    Warnings

  • Peripheral neuropathy: May cause numbness, tingling, or pain in hands/feet.
  • Blood disorders: Risk of thrombocytopenia, neutropenia, and anemia.
  • Cardiac risk: Heart failure and arrhythmias have been reported.
  • Pulmonary toxicity: Rare cases of acute respiratory distress.
  • Pregnancy risk: Can harm an unborn baby; contraception required during and after treatment.

    • Precautions

  • Monitor blood counts regularly.
  • Use caution in patients with pre‑existing neuropathy or cardiac disease.
  • Avoid live vaccines during treatment.
  • Breastfeeding is not recommended during therapy and for at least 2 months after the last dose.

    • Common Side Effects

  • Fatigue
  • Nausea, vomiting, diarrhea, constipation
  • Loss of appetite
  • Peripheral neuropathy (tingling, numbness)
  • Thrombocytopenia (low platelets)
  • Neutropenia (low white cells)
  • Anemia
  • Fever, infections

    • Serious but Rare Side Effects

  • Severe neuropathy
  • Cardiac failure
  • Pulmonary complications
  • Hepatic toxicity

    • FAQ - Bortezomib

    1What is Bortezomib Injection used for?
    Bortezomib Injection is used to treat multiple myeloma and mantle‑cell lymphoma, two types of blood cancer. It helps slow down cancer cell growth, reduce symptoms, and improve treatment results.
    2What side effects should I expect?
    Common side effects include tiredness, nausea, vomiting, loss of appetite, dizziness, and low blood cell counts. Because blood cells may decrease, patients are more prone to infections. Regular blood tests are required to monitor blood counts, heart, liver, and uric acid levels.
    3Can foreign patients buy Bortezomib Injection from India?
    Yes. Bortezomib Injection is available for international patients through licensed exporters in India. A valid doctor’s prescription is required, and shipments are arranged with temperature‑controlled packaging to maintain medicine quality during transit.
    4How is Bortezomib Injection shipped overseas?
    Medicines are shipped using secure courier partners logistics. Export documentation, customs clearance, and regulatory compliance are handled to ensure safe delivery to countries in the EU, US, Middle East, Africa, and Asia.
    5Is Bortezomib Injection affordable for foreign patients?
    Yes. India is a leading supplier of cost effective generic oncology medicines. Bortezomib Injection is offered at competitive export prices, making cancer treatment more affordable compared to many Western markets.
    6What documents are required for international supply?
    Foreign patients or buyers must provide:
  • A valid prescription from a licensed doctor
  • Patient ID proof for named patient programs
    • 7How do foreign patients ensure medicine authenticity?
    Bortezomib Injection is sourced directly from authorized manufacturers and distributors. Each pack comes with batch number, expiry date, and manufacturer details. Exporters provide invoice.
    8Which countries can receive Bortezomib Injection exports?
    Bortezomib Injection is shipped to over 50 countries, including the United States, United Kingdom, Germany, UAE, Saudi Arabia, South Africa, and Latin America. Delivery timelines vary depending on customs clearance and local regulations.

    References

  • Takeda Pharmaceuticals U.S.A., Inc., U.S. Food and Drug Administration (FDA), [Revised on August 2022], [Accessed on November 30, 2022], Prescribing Information – Velcade (2022) Prescribing Information
  • STADA, Electronic Medicines Compendium (EMC), [Revised on November 2021], [Accessed on November 30, 2022], Patient Information Leaflet – STADA (2021) Patient Information Leaflet

    • Medical Disclaimer

    The information provided on this page is for educational and informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Bortezomib Injection should only be used under the supervision of a qualified healthcare professional. Always consult your doctor or healthcare provider before starting, stopping, or changing any medication. Do not ignore professional medical advice or delay seeking treatment based on the information provided on this website.

    Biosyn Pharmaceuticals supplies prescription medicines in accordance with applicable laws and regulations. International orders may require a valid prescription and are subject to the import regulations of the destination country. Patients should consult their healthcare provider before purchasing or using any prescription medicine.